Donor-derived natural killer cells infused after human leukocyte antigen-haploidentical hematopoietic cell transplantation: a dose-escalation study

Cited 98 time in scopus
Metadata Downloads

Full metadata record

DC FieldValueLanguage
dc.contributor.authorIn Pyo Choi-
dc.contributor.authorSuk Ran Yoon-
dc.contributor.authorSoo Yeon Park-
dc.contributor.authorHanna Kim-
dc.contributor.authorSol-Ji Jung-
dc.contributor.authorYe Jin Jang-
dc.contributor.authorMin Ho Kang-
dc.contributor.authorYoung Il Yeom-
dc.contributor.authorJ L Lee-
dc.contributor.authorD Y Kim-
dc.contributor.authorY S Lee-
dc.contributor.authorY A Kang-
dc.contributor.authorM Jeon-
dc.contributor.authorM Seol-
dc.contributor.authorJ H Lee-
dc.contributor.authorJ H Lee-
dc.contributor.authorH J Kim-
dc.contributor.authorS C Yun-
dc.contributor.authorK H Lee-
dc.date.accessioned2017-04-19T09:52:39Z-
dc.date.available2017-04-19T09:52:39Z-
dc.date.issued2014-
dc.identifier.issn1083-8791-
dc.identifier.uri10.1016/j.bbmt.2014.01.031ko
dc.identifier.urihttps://oak.kribb.re.kr/handle/201005/11944-
dc.description.abstractThe doses of donor-derived natural killer (NK) cells that can be given safely after human leukocyte antigen (HLA)-haploidentical hematopoietic cell transplantation (HCT) remain to be defined. Forty-one patients (ages 17 to 75years) with hematologic malignancy underwent HLA-haploidentical HCT after reduced-intensity conditioning containing busulfan, fludarabine, and antithymocyte globulin. Cell donors (ages 7 to 62years) underwent growth factor-mobilized leukapheresis for 3 to 4days. Cells collected on the first 2 to 3days were used for HCT, whereas those collected on the last day were CD3-depleted and cultured into NK cells using human interleukins-15 and -21. These NK cells were then infused into patients twice at 2 and 3weeks after HCT at an escalating doses of.2×108cells/kg of body weight (3 patients), 5×108cells/kg (3 patients), 1.0×108cells/kg (8 patients), and ≥ 1.0×108cells/kg or available cells (27 patients). At all dose levels, no acute toxicity was observed after NK cell infusion. After HLA-haploidentical HCT and subsequent donor NK cell infusion, when referenced to 31 historical patients who had undergone HLA-haploidentical HCT after the same conditioning regimen but without high-dose NK cell infusion, there was no significant difference in the cumulative incidences of major HCT outcomes, including engraftment (absolute neutrophil count≥500/μL, 85% versus 87%), grade 2 to 4 acute graft-versus-host disease (GVHD, 17% versus 16%), moderate to severe chronic GVHD (15% versus 10%), and transplantation-related mortality (27% versus 19%). There was, however, a significant reduction in leukemia progression (74% to 46%), with post-transplantation NK cell infusion being an independent predictor for less leukemia progression (hazard ratio, 527). Our findings showed that, when given 2 to 3weeks after HLA-haploidentical HCT, donor-derived NK cells were well tolerated at a median total dose of 2.0×108cells/kg. In addition, they may decrease post-transplantation progression of acute leukemia.-
dc.publisherElsevier-
dc.titleDonor-derived natural killer cells infused after human leukocyte antigen-haploidentical hematopoietic cell transplantation: a dose-escalation study-
dc.title.alternativeDonor-derived natural killer cells infused after human leukocyte antigen-haploidentical hematopoietic cell transplantation: a dose-escalation study-
dc.typeArticle-
dc.citation.titleBiology of Blood and Marrow Transplantation-
dc.citation.number5-
dc.citation.endPage704-
dc.citation.startPage696-
dc.citation.volume20-
dc.contributor.affiliatedAuthorIn Pyo Choi-
dc.contributor.affiliatedAuthorSuk Ran Yoon-
dc.contributor.affiliatedAuthorSoo Yeon Park-
dc.contributor.affiliatedAuthorHanna Kim-
dc.contributor.affiliatedAuthorSol-Ji Jung-
dc.contributor.affiliatedAuthorYe Jin Jang-
dc.contributor.affiliatedAuthorMin Ho Kang-
dc.contributor.affiliatedAuthorYoung Il Yeom-
dc.contributor.alternativeName최인표-
dc.contributor.alternativeName윤석란-
dc.contributor.alternativeName박수연-
dc.contributor.alternativeName김한나-
dc.contributor.alternativeName정솔지-
dc.contributor.alternativeName장예진-
dc.contributor.alternativeName강민호-
dc.contributor.alternativeName염영일-
dc.contributor.alternativeName이재련-
dc.contributor.alternativeName김대영-
dc.contributor.alternativeName이영신-
dc.contributor.alternativeName강영아-
dc.contributor.alternativeName전미진-
dc.contributor.alternativeName설미애-
dc.contributor.alternativeName이정희-
dc.contributor.alternativeName이제환-
dc.contributor.alternativeName김화정-
dc.contributor.alternativeName윤성철-
dc.contributor.alternativeName이규형-
dc.identifier.bibliographicCitationBiology of Blood and Marrow Transplantation, vol. 20, no. 5, pp. 696-704-
dc.identifier.doi10.1016/j.bbmt.2014.01.031-
dc.subject.keywordDonor natural killer cell infusion-
dc.subject.keywordHuman leukocyte antigen-haploidentical hematopoietic cell transplantation-
dc.subject.localDonor natural killer (NK) cell infusion-
dc.subject.localdonor NK cell infusion-
dc.subject.localDonor natural killer cell infusion-
dc.subject.localHuman leukocyte antigen-haploidentical hematopoietic cell transplantation-
dc.description.journalClassY-
Appears in Collections:
Division of Biomedical Research > Immunotherapy Research Center > 1. Journal Articles
Aging Convergence Research Center > 1. Journal Articles
Division of Biomedical Research > Personalized Genomic Medicine Research Center > 1. Journal Articles
Files in This Item:
  • There are no files associated with this item.


Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.